CLEVELAND, March 06, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics announced today that NM3086, the lead clinical asset in its Properdin-associated Alternative Pathway (AP) program, demonstrated ...
Knowledge in immunology has been advanced by recent research. A new paper presents significant new findings about the protein properdin -- an important part of the immune system. It is a positive ...
NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway. The Food and Drug Administration (FDA) has granted Orphan ...
CLEVELAND, June 05, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin ...
Novelmed Therapeutics Inc. has reported topline results with its lead anti-properdin antibody NM-3086 in a rabbit model of paroxysmal nocturnal hemoglobinuria (PNH). NM-3086 is a potent, ...
A University of Leicester researcher has discovered how a protein in the blood – linked to defence against meningitis - plays a more vital role than previously understood in the body’s immune defence ...
We are at a critical time and supporting climate journalism is more important than ever. Science News and our parent organization, the Society for Science, need your help to strengthen environmental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback